JP2017532021A - コドン最適化組み換えプラスミド、末梢神経再生の刺激方法、及び損傷ヒト神経の治療様式 - Google Patents
コドン最適化組み換えプラスミド、末梢神経再生の刺激方法、及び損傷ヒト神経の治療様式 Download PDFInfo
- Publication number
- JP2017532021A JP2017532021A JP2017512743A JP2017512743A JP2017532021A JP 2017532021 A JP2017532021 A JP 2017532021A JP 2017512743 A JP2017512743 A JP 2017512743A JP 2017512743 A JP2017512743 A JP 2017512743A JP 2017532021 A JP2017532021 A JP 2017532021A
- Authority
- JP
- Japan
- Prior art keywords
- nerve
- vegf
- peripheral nerve
- codon
- gene therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000005036 nerve Anatomy 0.000 title claims abstract description 41
- 239000013612 plasmid Substances 0.000 title claims abstract description 38
- 210000000578 peripheral nerve Anatomy 0.000 title claims abstract description 32
- 230000008929 regeneration Effects 0.000 title claims abstract description 22
- 238000011069 regeneration method Methods 0.000 title claims abstract description 22
- 238000000034 method Methods 0.000 title claims description 14
- 230000000638 stimulation Effects 0.000 title description 6
- 238000011277 treatment modality Methods 0.000 title description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims abstract description 38
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims abstract 3
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 230000006698 induction Effects 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 abstract description 39
- 238000001415 gene therapy Methods 0.000 abstract description 20
- 208000014674 injury Diseases 0.000 abstract description 18
- 238000001356 surgical procedure Methods 0.000 abstract description 10
- 230000008733 trauma Effects 0.000 abstract description 10
- 238000011282 treatment Methods 0.000 abstract description 9
- 108020004705 Codon Proteins 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 7
- 108050007372 Fibroblast Growth Factor Proteins 0.000 abstract 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 abstract 2
- 229940126864 fibroblast growth factor Drugs 0.000 abstract 2
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 34
- 239000003102 growth factor Substances 0.000 description 23
- 208000027418 Wounds and injury Diseases 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 11
- 208000010886 Peripheral nerve injury Diseases 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 230000006378 damage Effects 0.000 description 10
- 230000007659 motor function Effects 0.000 description 10
- 239000000835 fiber Substances 0.000 description 9
- 210000003811 finger Anatomy 0.000 description 9
- 210000001617 median nerve Anatomy 0.000 description 9
- 210000003205 muscle Anatomy 0.000 description 8
- 210000004116 schwann cell Anatomy 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 210000000658 ulnar nerve Anatomy 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 6
- 210000003414 extremity Anatomy 0.000 description 6
- 210000000245 forearm Anatomy 0.000 description 6
- 230000030214 innervation Effects 0.000 description 6
- 210000000278 spinal cord Anatomy 0.000 description 6
- 230000003872 anastomosis Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 208000026721 nail disease Diseases 0.000 description 5
- 230000003248 secreting effect Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 4
- 206010028289 Muscle atrophy Diseases 0.000 description 4
- 208000028389 Nerve injury Diseases 0.000 description 4
- 230000033115 angiogenesis Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000002567 autonomic effect Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000020763 muscle atrophy Effects 0.000 description 4
- 201000000585 muscular atrophy Diseases 0.000 description 4
- 230000008764 nerve damage Effects 0.000 description 4
- 208000030212 nutrition disease Diseases 0.000 description 4
- 230000001172 regenerating effect Effects 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 210000003497 sciatic nerve Anatomy 0.000 description 4
- 210000004243 sweat Anatomy 0.000 description 4
- 108700024394 Exon Proteins 0.000 description 3
- 101150019331 FGF2 gene Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000002638 denervation Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000004005 microsphere Substances 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 208000033808 peripheral neuropathy Diseases 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 210000001364 upper extremity Anatomy 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
- 208000034656 Contusions Diseases 0.000 description 2
- 101100372758 Danio rerio vegfaa gene Proteins 0.000 description 2
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 2
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 2
- 229920002971 Heparan sulfate Polymers 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 2
- 206010039670 Sciatic nerve injury Diseases 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 101150030763 Vegfa gene Proteins 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000010442 axonal sprouting Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000004709 cell invasion Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 230000009519 contusion Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 102000058223 human VEGFA Human genes 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 230000000324 neuroprotective effect Effects 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 238000011477 surgical intervention Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000003813 thumb Anatomy 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 1
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 1
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 208000025962 Crush injury Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010027067 Median nerve injury Diseases 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 208000005890 Neuroma Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 230000021699 Schwann cell migration Effects 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010045378 Ulnar nerve injury Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 210000000467 autonomic pathway Anatomy 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000008209 cardiovascular development Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000005226 corpus cavernosum Anatomy 0.000 description 1
- 210000003618 cortical neuron Anatomy 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000009986 erectile function Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 101150016624 fgfr1 gene Proteins 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 210000004884 grey matter Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 230000008537 heat pain sensitivity Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000002743 insertional mutagenesis Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000004932 little finger Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 238000002406 microsurgery Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 230000004766 neurogenesis Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000009417 prefabrication Methods 0.000 description 1
- 210000002979 radial nerve Anatomy 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000007832 reinnervation Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 102220240796 rs553605556 Human genes 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 210000003594 spinal ganglia Anatomy 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000002972 tibial nerve Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000000623 ulna Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
- C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
末梢神経再生のための、ヌクレオチド配列番号1に表されるVEGF及びFGF2コード遺伝子を含むコドン最適化組み換えプラスミドpBud(Kan)‐coVEGF‐coFGF2;
術中又は術後期間内に、配列番号1に表されるコドン最適化組み換えプラスミドpBud(Kan)‐coVEGF‐coFGF2を神経内、神経周辺及び神経傍に投与することによる末梢神経再生のための刺激技術。
請求項1に記載の損傷領域に有効量のプラスミドpBud(Kan)‐coVEGF‐coFGF2を注入することによる損傷ヒト神経の治療様式。
栄養障害:
a)皮膚の状態:正常な色、指の温度低下、冷感の増加;
b)正常な腕と比較して、手及び前腕の筋肉の萎縮;2cm超(図2〜3);
c)爪の変化:低形成;
d)分泌機能(発汗):減少。
a)皮膚の状態:正常な色;
b)正常な腕と比較して、手及び前腕の筋肉の萎縮‐2cm超(図8);
c)爪の変化:低形成;
d)分泌機能(発汗):減少。
栄養障害:
a)皮膚の状態:正常な色;
b)正常な腕と比較して、手及び前腕の筋肉の萎縮‐中程度(1〜2cm)、及び重度‐2cm超;
c)爪の変化:正常範囲内;
d)分泌機能(発汗):正常。
1)円柱形状把持‐YES
2)球状把持‐YES
3)フック把持(バッグの持ち手)‐YES
4)拳把持‐YES
5)チップ把握
a)末端反対側把持‐YES
b)(末端付近反対側把持‐NO)
6)側部把握
a)ピンチグリップ‐NO
b)(はさみグリップ‐「煙草」)‐NO。
2012年4月20日の身体検査の結果:
栄養障害:
a)皮膚の状態:正常な色;
b)正常な腕と比較して、手及び前腕の筋肉の萎縮‐中程度、1〜2cm;
c)爪の変化:正常範囲内;
d)分泌機能:正常範囲内。
1)円柱形状把持‐YES
2)球状把持‐YES
3)フック把持‐YES(図9)
4)拳把持‐YES(図10)
5)チップ把握:(図11〜13)
a)末端反対側把持‐YES
b)(末端付近反対側把持‐YES)
6)側部把握
a)ピンチグリップ‐YES
b)はさみグリップ‐YES。
<110> OOO≪НекстГен≫、LLC「NextGen」
<120> コドン最適化組み換えプラスミド、末梢神経再生のための刺激技術、損傷ヒト神経の治療様式
<160> 1
<170> PatentIn バージョン3.5
<211> 5701
<212> DNA
<213> 人工配列
<223> 発現プラスミド
gcgcgcgttgacattgattattgactagttattaatagtaatcaattacggggtcattag 60
ttcatagcccatatatggagttccgcgttacataacttacggtaaatggcccgcctggct 120
gaccgcccaacgacccccgcccattgacgtcaataatgacgtatgttcccatagtaacgc 180
caatagggactttccattgacgtcaatgggtggactatttacggtaaactgcccacttgg 240
cagtacatcaagtgtatcatatgccaagtacgccccctattgacgtcaatgacggtaaat 300
ggcccgcctggcattatgcccagtacatgaccttatgggactttcctacttggcagtaca 360
tctacgtattagtcatcgctattaccatggtgatgcggttttggcagtacatcaatgggc 420
gtggatagcggtttgactcacggggatttccaagtctccaccccattgacgtcaatggga 480
gtttgttttggcaccaaaatcaacgggactttccaaaatgtcgtaacaactccgccccat 540
tgacgcaaatgggcggtaggcgtgtacggtgggaggtctatataagcagagctctctggc 600
taactagagaacccactgcttactggcttatcgaaattaatacgactcactatagggaga 660
cccaagcttacaagtttgtacaaaaaagcaggctcaccatggcagccgggagcatcacca 720
cgctgcccgccttgcccgaggatggcggcagcggcgccttcccgcccggccacttcaagg 780
accccaagcggctgtactgcaaaaacgggggcttcttcctgcgcatccaccccgacggcc 840
gagttgacggggtccgggagaagagcgaccctcacatcaagctacaacttcaagcagaag 900
agagaggagttgtgtctatcaaaggagtgtgtgctaaccgttacctggctatgaaggaag 960
atggaagattactggcttctaaatgtgttacggatgagtgtttcttttttgaacgattgg 1020
aatctaataactacaatacttaccggtcaaggaaatacaccagttggtatgtggcactga 1080
aacgaactgggcagtataaacttggatccaaaacaggacctgggcagaaagctatacttt 1140
ttcttccaatgtctgctaagagctgaacccagctttcttgtacaaagtggtgtttgatcc 1200
ccgggaattcagacatgataagatacattgatgagtttggacaaaccacaactagaatgc 1260
agtgaaaaaaatgctttatttgtgaaatttgtgatgctattgctttatttgtaaccatta 1320
taagctgcaataaacaagttggggtgggcgaagaactccagcatgagatccccgcgctgg 1380
aggatcatccagccggcgtcccggaaaacgattccgaagcccaacctttcatagaaggcg 1440
gcggtggaatcgaaatctcgtagcacgtggtctgacgctcagtggaacgacgcgtaactc 1500
acgttaagggattttggtcatgagcttgcgccgtcccgtcaagtcagcgtaatgctctgc 1560
cagtgttacaaccaattaaccaattctgattagaaaaactcatcgagcatcaaatgaaac 1620
tgcaatttattcatatcaggattatcaataccatatttttgaaaaagccgtttctgtaat 1680
gaaggagaaaactcaccgaggcagttccataggatggcaagatcctggtatcggtctgcg 1740
attccgactcgtccaacatcaatacaacctattaatttcccctcgtcaaaaataaggtta 1800
tcaagtgagaaatcaccatgagtgacgactgaatccggtgagaatggcaaaagtttatgc 1860
atttctttccagacttgttcaacaggccagccattacgctcgtcatcaaaatcactcgca 1920
tcaaccaaaccgttattcattcgtgattgcgcctgagcgagacgaaatacgcgatcgctg 1980
ttaaaaggacaattacaaacaggaatcgaatgcaaccggcgcaggaacactgccagcgca 2040
tcaacaatattttcacctgaatcaggatattcttctaatacctggaatgctgtttttccg 2100
gggatcgcagtggtgagtaaccatgcatcatcaggagtacggataaaatgcttgatggtc 2160
ggaagaggcataaattccgtcagccagtttagtctgaccatctcatctgtaacatcattg 2220
gcaacgctacctttgccatgtttcagaaacaactctggcgcatcgggcttcccatacaag 2280
cgatagattgtcgcacctgattgcccgacattatcgcgagcccatttatacccatataaa 2340
tcagcatccatgttggaatttaatcgcggcctcgacgtttcccgttgaatatggctcata 2400
acaccccttgtattactgtttatgtaagcagacagttttattgttcatgatgatattatt 2460
ttatcttgtgcaatgtaacatcagagattttgagacacgggccagagctgctcgtcgagc 2520
tagcttcgtgaggctccggtgcccgtcagtgggcagagcgcacatcgcccacagtccccg 2580
agaagttggggggaggggtcggcaattgaaccggtgcctagagaaggtggcgcggggtaa 2640
actgggaaagtgatgtcgtgtactggctccgcctttttcccgagggtgggggagaaccgt 2700
atataagtgcagtagtcgccgtgaacgttctttttcgcaacgggtttgccgccagaacac 2760
aggtaagtgccgtgtgtggttcccgcgggcctggcctctttacgggttatggcccttgcg 2820
tgccttgaattacttccacctggctccagtacgtgattcttgatcccgagctggagccag 2880
gggcgggccttgcgctttaggagccccttcgcctcgtgcttgagttgaggcctggcctgg 2940
gcgctggggccgccgcgtgcgaatctggtggcaccttcgcgcctgtctcgctgctttcga 3000
taagtctctagccatttaaaatttttgatgacctgctgcgacgctttttttctggcaaga 3060
tagtcttgtaaatgcgggccaggatctgcacactggtatttcggtttttgggcccgcggc 3120
cggcgacggggcccgtgcgtcccagcgcacatgttcggcgaggcggggcctgcgagcgcg 3180
gccaccgagaatcggacgggggtagtctcaagctggccggcctgctctggtgcctggcct 3240
cgcgccgccgtgtatcgccccgccctgggcggcaaggctggcccggtcggcaccagttgc 3300
gtgagcggaaagatggccgcttcccggccctgctccagggggctcaaaatggaggacgcg 3360
gcgctcgggagagcgggcgggtgagtcacccacacaaaggaaaagggcctttccgtcctc 3420
agccgtcgcttcatgtgactccacggagtaccgggcgccgtccaggcacctcgattagtt 3480
ctggagcttttggagtacgtcgtctttaggttggggggaggggttttatgcgatggagtt 3540
tccccacactgagtgggtggagactgaagttaggccagcttggcacttgatgtaattctc 3600
gttggaatttgccctttttgagtttggatcttggttcattctcaagcctcagacagtggt 3660
tcaaagtttttttcttccatttcaggtgtcgtgaacacgtggtcgcggccgcaagcttca 3720
ccatgaactttctgctgtcttgggtgcattggagccttgccttgctgctctacctccacc 3780
atgccaagtggtcccaggctgcacccatggcagaaggaggagggcagaatcatcacgaag 3840
tggtgaagttcatggatgtctatcagcgcagctactgccatccaatcgagaccctggtgg 3900
acatcttccaggagtaccctgatgagatcgagtacatcttcaagccatcctgtgtgcccc 3960
tgatgcgatgcgggggctgctgcaatgacgagggcctggagtgtgtgcccactgaggagt 4020
ccaacatcaccatgcagattatgcggatcaaacctcaccaaggccagcacataggagaga 4080
tgagcttcctacagcacaacaaatgtgaatgcagaccaaagaaagatagagcaagacaag 4140
aaaatccctgtgggccttgctcagagcggagaaagcatttgtttgtacaagatccgcaga 4200
cgtgtaaatgttcctgcaaaaacacagactcgcgttgcaaggcgaggcagcttgagttaa 4260
acgaacgtacttgcagatgtgacaagccgaggcggtgatctagagtttaaacccgctgat 4320
cagcctcgactgtgccttctagttgccagccatctgttgtttgcccctcccccgtgcctt 4380
ccttgaccctggaaggtgccactcccactgtcctttcctaataaaatgaggaaattgcat 4440
cgcattgtctgagtaggtgtcattctattctggggggtggggtggggcaggacagcaagg 4500
gggaggattgggaagacaatagcaggcatgctggggatgcggtgggctctatggcttctg 4560
aggcggaaagaaccagtggcggtaatacggttatccacagaatcaggggataacgcagga 4620
aagaacatgtgagcaaaaggccagcaaaaggccaggaaccgtaaaaaggccgcgttgctg 4680
gcgtttttccataggctccgcccccctgacgagcatcacaaaaatcgacgctcaagtcag 4740
aggtggcgaaacccgacaggactataaagataccaggcgtttccccctggaagctccctc 4800
gtgcgctctcctgttccgaccctgccgcttaccggatacctgtccgcctttctcccttcg 4860
ggaagcgtggcgctttctcatagctcacgctgtaggtatctcagttcggtgtaggtcgtt 4920
cgctccaagctgggctgtgtgcacgaaccccccgttcagcccgaccgctgcgccttatcc 4980
ggtaactatcgtcttgagtccaacccggtaagacacgacttatcgccactggcagcagcc 5040
actggtaacaggattagcagagcgaggtatgtaggcggtgctacagagttcttgaagtgg 5100
tggcctaactacggctacactagaaggacagtatttggtatctgcgctctgctgaagcca 5160
gttaccttcggaaaaagagttggtagctcttgatccggcaaacaaaccaccgctggtagc 5220
ggtggtttttttgtttgcaagcagcagattacgcgcagaaaaaaaggatctcaagaagat 5280
cctttgatcttttctacggggtctgacgctcagtggaacgaaaactcacgttaagggatt 5340
ttggtcatgacattaacctataaaaataggcgtatcacgaggccctttcgtctcgcgcgt 5400
ttcggtgatgacggtgaaaacctctgacacatgcagctcccggagacggtcacagcttgt 5460
ctgtaagcggatgccgggagcagacaagcccgtcagggcgcgtcagcgggtgttggcggg 5520
tgtcggggctggcttaactatgcggcatcagagcagattgtactgagagtgcaccatata 5580
tgcggtgtgaaataccgcacagatgcgtaaggagaaaataccgcatcaggcgccattcgc 5640
cattcaggctgcgcaactgttgggaagggcgatcggtgcgggcctcttcgctattacgcc 5700
a
カナマイシン耐性遺伝子‐1469〜2511
遺伝子FGF2cDNA(コドン組成により最適化された)‐699〜1166
遺伝子VEGF165cDNA(コドン組成により最適化された)‐3723〜4297
コザック配列‐695〜698及び3719〜3722。
Claims (3)
- 末梢神経再生のための、ヌクレオチド配列番号1に表されるVEGF及びFGF2コード遺伝子を含むコドン最適化組み換えプラスミドpBud(Kan)‐coVEGF‐coFGF2。
- 術中又は術後期間内に、配列番号1に表されるコドン最適化組み換えプラスミドpBud(Kan)‐coVEGF‐coFGF2を神経内、神経周辺及び神経傍に投与することによる末梢神経再生のための誘導技術。
- 請求項1に記載の損傷領域に有効量のプラスミドpBud(Kan)‐coVEGF‐coFGF2を注入することによる損傷ヒト神経の治療様式。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2014137218/10A RU2558294C1 (ru) | 2014-09-16 | 2014-09-16 | Кодон-оптимизированная рекомбинантная плазмида, способ стимуляции регенерации периферического нерва, способ лечения поврежденного нерва человека |
RU2014137218 | 2014-09-16 | ||
PCT/RU2015/000545 WO2016163912A1 (ru) | 2014-09-16 | 2015-08-27 | Кодон-оптимизированная рекомбинантная плазмида, способ стимуляции регенерации периферического нерва, способ лечения поврежденного нерва человека |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017532021A true JP2017532021A (ja) | 2017-11-02 |
JP6540797B2 JP6540797B2 (ja) | 2019-07-10 |
Family
ID=53762789
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017512743A Active JP6540797B2 (ja) | 2014-09-16 | 2015-08-27 | コドン最適化組み換えプラスミド、末梢神経再生の刺激方法、及び損傷ヒト神経の治療様式 |
Country Status (10)
Country | Link |
---|---|
US (2) | US20170189488A1 (ja) |
EP (1) | EP3196307B1 (ja) |
JP (1) | JP6540797B2 (ja) |
CN (1) | CN107087417A (ja) |
AU (1) | AU2015390821B2 (ja) |
BR (1) | BR112017005310B1 (ja) |
CA (1) | CA2960371C (ja) |
MX (1) | MX2017003377A (ja) |
RU (1) | RU2558294C1 (ja) |
WO (1) | WO2016163912A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2614665C1 (ru) * | 2015-12-18 | 2017-03-28 | федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) | Способ стимуляции репаративного ангиогенеза и регенерации соединительной ткани, при её повреждении, методом генной терапии с использованием видоспецифичных генов белковых факторов vegf и fgf2, в ветеринарии, и генетическая конструкция для реализации заявленного способа |
KR102592673B1 (ko) | 2016-05-25 | 2023-10-24 | 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 | 면역요법의 방법 |
RU2639175C1 (ru) * | 2016-11-14 | 2017-12-20 | Общество с ограниченной ответственностью "НекстГен" | Способ индукции регенерации периферического нерва |
CA3050299A1 (en) * | 2017-01-20 | 2018-07-26 | Atara Biotherapeutics, Inc. | Methods of treating multiple sclerosis using autologous t cells |
RU2762855C1 (ru) * | 2021-04-08 | 2021-12-23 | федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) | Генно-клеточный везикулярный терапевтический препарат и способ терапии рассеянного склероза посредством трансплантации генно-клеточного везикулярного терапевтического препарата |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE418346T1 (de) * | 2004-04-08 | 2009-01-15 | Sangamo Biosciences Inc | Zusammensetzungen zur behandlung von neuropathischen und neurodegenerativen erkrankungen |
US9169309B2 (en) * | 2011-03-01 | 2015-10-27 | Humanzyme Inc. | Thermostable variants of fibroblast growth factors |
RU2459630C1 (ru) * | 2011-04-27 | 2012-08-27 | Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Казанский (Приволжский) Федеральный Университет" (ФГАОУ ВПО КФУ) | Способ стимулирования нейрогенерации с помощью генетических конструкций |
RU2542385C2 (ru) * | 2012-08-31 | 2015-02-20 | Общество с ограниченной ответственностью "НекстГен" | Способ получения фармацевтической композиции для индукции развития кровеносных сосудов в тканях, фармацевтическая композиция, полученная этим способом, и способ лечения ишемии тканей и/или органов человека |
RU2517117C2 (ru) * | 2012-11-26 | 2014-05-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Казанский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО Казанский ГМУ Минздравсоцразвития России) | Способ стимулирования регенерации нерва с помощью наноструктурированного матрикса и генетических конструкций |
-
2014
- 2014-09-16 RU RU2014137218/10A patent/RU2558294C1/ru active
-
2015
- 2015-08-27 BR BR112017005310-1A patent/BR112017005310B1/pt active IP Right Grant
- 2015-08-27 CA CA2960371A patent/CA2960371C/en active Active
- 2015-08-27 MX MX2017003377A patent/MX2017003377A/es unknown
- 2015-08-27 JP JP2017512743A patent/JP6540797B2/ja active Active
- 2015-08-27 CN CN201580050094.6A patent/CN107087417A/zh active Pending
- 2015-08-27 EP EP15888619.2A patent/EP3196307B1/en active Active
- 2015-08-27 WO PCT/RU2015/000545 patent/WO2016163912A1/ru active Application Filing
- 2015-08-27 AU AU2015390821A patent/AU2015390821B2/en active Active
-
2017
- 2017-03-16 US US15/460,668 patent/US20170189488A1/en not_active Abandoned
- 2017-07-18 US US15/652,792 patent/US10434145B2/en active Active
Non-Patent Citations (5)
Title |
---|
CELL TECHNOLOGIES IN BIOLOGY AND MEDICINE, vol. 1, JPN6018051986, May 2014 (2014-05-01), pages 155-158 * |
J. MOL. NEUROSCI., vol. 47, JPN6018051985, 2012, pages 166-172 * |
КЛЕТОЧНАЯ ТРАНСПЛАНТОЛОГИЯ И ТКАНЕВАЯ ИНЖЕНЕРИЯ(CELLULAR, vol. 6 (3), JPN7018004370, 2011, pages 67-70 * |
ロシア国登録特許2459630号公報, JPN7018004368 * |
ロシア国登録特許2517117号公報, JPN7018004369 * |
Also Published As
Publication number | Publication date |
---|---|
CA2960371C (en) | 2019-06-25 |
RU2558294C1 (ru) | 2015-07-27 |
US10434145B2 (en) | 2019-10-08 |
WO2016163912A1 (ru) | 2016-10-13 |
US20170319658A1 (en) | 2017-11-09 |
AU2015390821B2 (en) | 2018-08-09 |
MX2017003377A (es) | 2017-11-22 |
AU2015390821A1 (en) | 2017-05-04 |
CN107087417A (zh) | 2017-08-22 |
EP3196307A1 (en) | 2017-07-26 |
BR112017005310B1 (pt) | 2023-10-03 |
CA2960371A1 (en) | 2016-10-13 |
BR112017005310A2 (pt) | 2018-02-14 |
JP6540797B2 (ja) | 2019-07-10 |
EP3196307B1 (en) | 2018-12-26 |
US20170189488A1 (en) | 2017-07-06 |
EP3196307A4 (en) | 2018-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10434145B2 (en) | Codon-optimized recombinant plasmid, method of stimulating peripheral nerve regeneration, and method of treating nerve damage in humans | |
Ramer et al. | Setting the stage for functional repair of spinal cord injuries: a cast of thousands | |
Raimondo et al. | Combined delivery of VEGF and IGF-1 promotes functional innervation in mice and improves muscle transplantation in rabbits | |
Yamaya et al. | Low-energy extracorporeal shock wave therapy promotes vascular endothelial growth factor expression and improves locomotor recovery after spinal cord injury | |
Ma et al. | Linear ordered collagen scaffolds loaded with collagen-binding basic fibroblast growth factor facilitate recovery of sciatic nerve injury in rats | |
Kucuk et al. | Effects of platelet-rich plasma on nerve regeneration in a rat model | |
WO2008096268A2 (en) | Autologous lymph node transfer in combination with vegf-c or vegf-d growth factor therapy to treat secondary lymphedema and to improve reconstructive surgery | |
Yao et al. | Tetrahedral framework nucleic acids facilitate neurorestoration of facial nerves by activating the NGF/PI3K/AKT pathway | |
Parikh et al. | Intramuscular E-selectin/adeno-associated virus gene therapy promotes wound healing in an ischemic mouse model | |
US20140087002A1 (en) | Autologous Lymph Node Transfer In Combination With VEGF-C Or VEGF-D Growth Factor Therapy to Treat Lymphedema And To Improve Reconstructive Surgery | |
RU2486918C1 (ru) | Способ стимулирования восстановления периферической иннервации тканей с помощью векторных конструкций | |
Van Brunt et al. | Growth factors speed wound healing | |
RU2639175C1 (ru) | Способ индукции регенерации периферического нерва | |
Isner | Manipulating angiogenesis against vascular disease | |
RU2449799C2 (ru) | Средство для осуществления терапевтического ангиогенеза и способ его осуществления | |
JP5849109B2 (ja) | 神経保護効果のある化合物 | |
RU2614665C1 (ru) | Способ стимуляции репаративного ангиогенеза и регенерации соединительной ткани, при её повреждении, методом генной терапии с использованием видоспецифичных генов белковых факторов vegf и fgf2, в ветеринарии, и генетическая конструкция для реализации заявленного способа | |
RU2811302C1 (ru) | Способ восстановления нерва с помощью имплантата ствола нерва, содержащего фиброин шелка, в эксперименте | |
RU2663470C2 (ru) | Способ стимулирования ангиогенеза с использованием генетически модифицированных клеток крови пуповины | |
Rong et al. | Combination therapy of chitosan conduit and naringin facilitate regeneration of injured sciatic nerve in rats | |
Vera | A study of primary sensory neurons and Schwann cells sensitivity to visible light irradiation in vitro, and feasibility of a light inducible system in Schwann cells for neurite outgrowth enhancement in vitro | |
Ammanuel et al. | Peroneal Nerve Repair with Cross-Bridge Ladder Technique: Parallel End-to-Side Neurorrhaphies | |
Feng et al. | Efficacy of autologous epineurium small gap coaptation combined with platelet-rich plasma, nerve growth factor, and nerve fragments in the repair of damaged peripheral nerves | |
Sciboz et al. | THE ROLE OF NGF IN THE REGENERATION OF PERIPHERAL NERVE INJURY–SYSTEMATIC REVIEW–IMPLICATIONS FOR THE PROVISION OF DAYS OF MEDICAL CARE AFTER PERIPHERAL NERVE INJURIES | |
Cui et al. | Effect of Reneurorrhaphy of Distal Coaptation on Nerve Regeneration After Nerve Grafting: Animal Experimental Study |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180806 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20181016 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180928 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20181129 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190115 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190326 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20190326 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190514 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190527 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6540797 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |